DBC1 Inhibitors
DBC1 inhibitors constitute a diverse class of chemicals with distinct mechanisms of action, primarily targeting epigenetic modifiers, kinase activities, and signaling pathways implicated in DBC1-mediated cellular processes. A-196, a LSD1 inhibitor, indirectly impacts DBC1 by modulating histone methylation at key regulatory sites. GSK-J4, a demethylase inhibitor, influences DBC1 through epigenetic modifications, altering chromatin accessibility. BAY 1238097, an Mps1 kinase inhibitor, disrupts mitotic checkpoints, indirectly affecting DBC1-related cellular processes. NSC 23766, a Rac1 inhibitor, modulates cytoskeletal dynamics, influencing DBC1-associated migration and invasion pathways. Furthermore, bromodomain inhibitors like BRD4770 and JQ1 alter chromatin structure, indirectly affecting DBC1-related gene expression patterns. AZD7762, a CHK1 inhibitor, disrupts DNA damage responses, impacting DBC1-associated repair mechanisms. FH535, a Wnt/β-catenin pathway inhibitor, indirectly influences DBC1 by altering the transcriptional landscape associated with Wnt signaling. SB-3CT, a gelatinase inhibitor, modulates extracellular matrix dynamics, indirectly affecting DBC1-regulated signaling pathways.
Moreover, LY294002, a PI3K inhibitor, disrupts the PI3K/Akt pathway, influencing cellular processes intricately linked to DBC1. UNC1999, an EZH2 inhibitor, modulates histone methylation patterns, indirectly affecting the epigenetic landscape associated with DBC1. SP600125, a JNK inhibitor, disrupts stress response pathways, indirectly influencing cellular processes associated with JNK signaling and its cross-talk with DBC1. This array of inhibitors provides valuable tools for unraveling the intricacies of DBC1 regulation and its involvement in cellular pathways, laying the groundwork for precise experimental investigations.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-196 | 1982372-88-2 | sc-507414 | 1 mg | $72.00 | ||
A-196, a specific inhibitor targeting lysine-specific demethylase 1A (LSD1), influences the demethylation of histone H3 at lysine 4. By modulating this epigenetic process, A-196 indirectly impacts the transcriptional regulation of genes associated with the DBC1 pathway. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4, an H3K27me3 demethylase inhibitor, hinders the removal of histone marks associated with transcriptional repression. Its action on epigenetic modifications can indirectly affect DBC1 by influencing the accessibility of chromatin and altering gene expression patterns. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
AZD7762, a checkpoint kinase 1 (CHK1) inhibitor, disrupts DNA damage response pathways. The inhibition of CHK1 by AZD7762 indirectly influences DBC1 by perturbing cell cycle checkpoints and affecting DNA repair mechanisms associated with the DBC1 regulatory network. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a bromodomain and extraterminal (BET) protein inhibitor, targets epigenetic readers. Its impact on chromatin structure and transcriptional regulation indirectly influences DBC1 by altering the expression of genes associated with the cellular processes modulated by DBC1. | ||||||
β-Catenin/Tcf Inhibitor, FH535 | 108409-83-2 | sc-221398 sc-221398A | 10 mg 50 mg | $182.00 $374.00 | 7 | |
FH535, a Wnt/β-catenin signaling pathway inhibitor, disrupts the interaction between β-catenin and transcription factors. The modulation of this pathway indirectly affects DBC1 by altering the transcriptional landscape associated with Wnt signaling and its cross-talk with DBC1. | ||||||
SB-3CT | 292605-14-2 | sc-205847 sc-205847A | 1 mg 5 mg | $102.00 $388.00 | 15 | |
SB-3CT, a gelatinase inhibitor, targets matrix metalloproteinases. Its impact on extracellular matrix remodeling indirectly influences DBC1 by modulating cellular processes linked to matrix dynamics, which in turn affect the signaling pathways regulated by DBC1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor, disrupts the PI3K/Akt signaling pathway. This inhibition indirectly affects DBC1 by modulating downstream effectors involved in cell survival, proliferation, and metabolism, processes intricately linked to DBC1-mediated signaling. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999, an EZH2 histone methyltransferase inhibitor, modulates histone methylation patterns. Its impact on the epigenetic landscape indirectly influences DBC1 by altering the transcriptional regulation of genes associated with the cellular processes governed by DBC1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, disrupts the JNK signaling pathway. This inhibition indirectly influences DBC1 by modulating stress response pathways and altering cellular processes associated with JNK signaling and its cross-talk with DBC1. | ||||||